Investigators derived proteomic (ProtS) and metabolomic (MetS) summary scores for systolic and diastolic blood pressure and for hypertension with Elastic Net in the Multi‑Ethnic Study of Atherosclerosis (MESA). They then integrated those omics scores with established polygenic risk scores (PRS) across five incremental XGBoost models. The models trained in MESA were validated externally in the Jackson Heart Study (JHS). ProtS produced the highest external discrimination in JHS (AUC 0.68) and showed the smallest drop in performance when moved across cohorts, compared with MetS and PRS. This pattern suggests proteomic signatures captured cross-population signal that was more transportable than the other omics modalities evaluated.
The cohort in MESA provided the training ground where adding omics information increased predictive accuracy. The clinical baseline model discriminated incident hypertension at an AUC of 0.63. Adding the omics-derived scores raised that discrimination: the combined model reached an AUC of 0.72 in MESA. Measured blood pressure remained a potent predictor; when measured SBP and DBP were included, the PRS+BP model in MESA achieved an AUC of 0.80. The study team reported that ProtS had particularly strong effects on discrimination when measured BP was not in the model, reflecting its capacity to capture preclinical biology.
Measured SBP and DBP substantially improved model performance in both cohorts. In JHS, the baseline+BP model attained an AUC of 0.74, while in MESA the PRS+BP model achieved an AUC of 0.80. The authors reported that measured blood pressure outperformed individual omics modalities for incident hypertension prediction. However, in subgroups without baseline BP elevation, molecular scores supplied additional discriminatory power: among JHS participants with normal baseline BP, ProtS had the best discrimination when measured BP was not available (AUC 0.62), whereas PRS combined with BP reached an AUC of 0.69.
To reduce cross-cohort miscalibration, the investigators applied transfer learning techniques to adapt the MESA-derived XGBoost models to JHS. The specific procedure described in the abstract — leaf-weight refreshing — consistently improved calibration in the external cohort while largely preserving discrimination. The authors reported that calibration gains occurred without substantial loss of AUC, indicating that modest model adaptation can address cohort differences in baseline risk or feature distributions. The abstract did not list the full technical hyperparameters for the transfer-learning steps; those details may be in the full manuscript or supplementary material.
The study team prioritized Elastic Net–selected proteins for downstream causal inference and functional follow-up. They used Mendelian randomization and colocalization analyses to identify proteins associated with BP traits or hypertension. Mendelian randomization implicated 77 proteins that map to biologic processes including vascular regulation, inflammation, renal function, and natriuretic signaling. The authors interpreted these findings as evidence that proteins contributing to ProtS reflect plausible pathophysiologic mechanisms relevant to incident hypertension. The abstract did not provide the full list of implicated proteins or per-protein effect estimates; readers should consult the supplementary material or dataset for those annotations.
The investigators concluded that proteomic (ProtS) signals offered superior predictive performance and cross-cohort transferability among the omics modalities they tested, while measured blood pressure remained the dominant predictor of incident hypertension. They also noted that proteomic and genetic information could provide complementary biological signals useful for identifying individuals at elevated hypertension risk before clinical BP elevation occurs. The preprint indicates that some methodological details and full lists of proteins and metabolites are available in supplementary files and that TOPMed whole-genome sequence and phenotype data can be accessed via dbGaP under the reported accessions for JHS and MESA. The abstract did not enumerate limitations in detail; the source earlier framed the relative contributions of proteomic, metabolomic, and polygenic scores to incident hypertension risk as incompletely characterized, which remains an open question to be addressed in subsequent work.
Limitations and next steps documented in the source include the need to examine which specific proteins and metabolites drive ProtS and MetS performance across ancestries and to evaluate clinical utility in prospective, implementation-focused settings. Data availability and the study’s dbGaP accessions are provided in the preprint metadata for investigators seeking to replicate or extend these analyses.